AbbVie (ABBV) reports positive phase 1 multiple ascending dose results for ABBV-295, a long-acting amylin analog
Importance
Level 1
#ABBVIE INC#ABBV.US#EQUITIES#EU SESSION#US SESSION#BIOTECHNOLOGY#BIOTECHNOLOGY (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#ABBVIE INC#ABBV#US EQUITIES